Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TK1 | P04183 | 2/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | DUT | P33316 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20341349 | 1.00 | LMNA (0.52) | LMNAKIF11MAPK1TK1GRIN1 | |
| SCHEMBL4624290 | 1.00 | LMNA (0.52) | LMNAKIF11MAPK1TK1GRIN1 | |
| SCHEMBL10434091 | 0.88 | LMNA (0.46) | LMNAKIF11KCNH2 | |
| SCHEMBL10434128 | 0.88 | LMNA (0.46) | LMNAKIF11KCNH2 | |
| SCHEMBL24937040 | 0.88 | LMNA (0.46) | LMNAKIF11KCNH2 | |
| SCHEMBL10419038 | 0.86 | LMNA (0.43) | LMNAKIF11MAPK1TK1GRIN1 | |
| SCHEMBL18307295 | 0.85 | KIF11 (0.44) | LMNAKIF11TK1GRIN1GRIN2A | |
| SCHEMBL16281907 | 0.83 | KIF11 (0.50) | LMNAKIF11TK1GRIN1GRIN2A | |
| SCHEMBL10772460 | 0.83 | TK1 (0.54) | LMNAKIF11TK1GRIN1GRIN2A | |
| SCHEMBL2111572 | 0.83 | KIF11 (0.50) | LMNAKIF11TK1GRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631938-A1 | NITROGEN-CONTAINING HETEROCYCLE WITH SEROTONIN RECEPTOR-BINDING ACTIVITY AND CARBOCYCLIC DERIVATIVE | Shionogi & Co., Ltd (JP) | 2025-10-15 | — | — | EP | disclosed |
| US-20250115604-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2025-04-10 | — | — | US | disclosed |
| US-12157734-B2 | Sulfoximine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-12-03 | — | — | US | disclosed |
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| WO-2024122617-A1 | NITROGEN-CONTAINING HETEROCYCLE WITH SEROTONIN RECEPTOR-BINDING ACTIVITY AND CARBOCYCLIC DERIVATIVE | 塩野義製薬株式会社 | 2024-06-13 | — | — | WO | disclosed |
| WO-2024041573-A1 | FUSED MULTI-HETEROCYCLIC COMPOUNDS AS KRAS G12D MODULATORS AND USES THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2024-02-29 | — | — | WO | disclosed |
| EP-4308570-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425661-A | Macrocyclic LRRK2 kinase inhibitors | 法国施维雅药厂 | 2024-01-19 | — | — | CN | disclosed |
| CN-110770226-B | Sulfoximine glycosidase inhibitors | 阿森纽荣股份公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2022194976-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-09-22 | — | — | WO | disclosed |
| US-20120322764-A1 | Acyclic Nucleoside Phosphonate Derivatives and Medical Uses Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2012-12-20 | — | — | US | disclosed |
| EP-2511281-A1 | ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVES AND MEDICINE USES THEREOF | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China (CN) | 2012-10-17 | — | — | EP | disclosed |
| US-8269002-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| US-20120157431-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2012-06-21 | — | — | US | disclosed |
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| EP-2311827-A1 | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators. | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2301933-A1 | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-7838675-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2010-11-23 | — | — | US | disclosed |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| WO-2006024823-A9 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157734-B2 | Sulfoximine glycosidase inhibitors | ENGASE, BACE1, GAA | LMNA 1834/4885KIF11 3510/4885MAPK1 4229/4885 |
| US-20120322764-A1 | Acyclic Nucleoside Phosphonate Derivatives and Medical Uses Thereof | PNP, ENPP3, MTAP | LMNA 2048/4885KIF11 2846/4885MAPK1 2041/4885 |
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PARK7, PINK1 | LMNA 2450/4885KIF11 1526/4885MAPK1 117/4885 |
| US-20250115604-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | LMNA 1721/4885KIF11 3575/4885MAPK1 4170/4885 |
| US-20120157431-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | LMNA 4718/4885KIF11 3179/4885MAPK1 1024/4885 |
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | LMNA 4718/4885KIF11 3179/4885MAPK1 1024/4885 |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | LMNA 4778/4885KIF11 3209/4885MAPK1 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.